成都先导与Bridge Biotherapeutics携手推进新型抗癌药物研发

· 成都先导与Bridge Biotherapeutics 签订研究合作协议，以加速发现首创（first in class）抗癌新药的新型药物候选物。

· Bridge Biotherapeutics期望通过合作利用成都先导专有的DEL平台识别出新的具有潜在抗癌活性的候选药物，以加强其肿瘤药物管线。

【中国成都，2024年8月22日】成都先导药物开发股份有限公司（以下简称“成都先导”，股票代码：688222.SH）宣布与韩国临床阶段生物技术公司Bridge Biotherapeutics Inc.（以下简称“Bridge”，股票代码：KQ288330）签订合作研究协议。此次合作将基于从成都先导的DNA编码化合物库（DEL）中识别出的苗头化合物进一步开发用于癌症治疗的潜在候选药物。

Bridge计划通过开发针对未公开靶标的新型抗癌药物候选物来加强其现有的以EGFR抑制剂为核心的肺癌治疗药物管线。在过去一年中，Bridge通过初期研究已建立起独有的分析方法，以开发可对多种癌症产生显著疗效的新型靶向药物。此次与成都先导的合作预计将在未来一年内迅速推进有效化合物衍生、优化和先导化合物确认等工作。

成都先导是DEL技术开发及其在小分子新药研发领域应用的全球领导者，其DEL技术平台拥有包含超过1.2万亿DNA编码化合物的实体分子库，公司拥有的DEL产品以及高效筛选能力已为全球多个机构和组织提供新药发现服务及项目。过去几年间，成都先导的药物发现与优化平台能力得到了极大提升，已逐步成长为拥有DNA编码化合物库技术（包括DEL库的设计、合成和筛选及拓展应用）、基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、寡聚核酸新药研发平台相关技术（STO）与靶向蛋白降解平台相关技术（TPD）等四个核心技术平台以及其他关键新药研发能力的生物技术公司。

Bridge Biotherapeutics首席执行官James Lee表示：

“我们相信与成都先导的合作将加速推进公司的新型靶向抗癌药物开发进程。基因突变型癌症是当前药物研发的重大难题之一，我们将不畏挑战，积极开发能对此类癌症产生疗效的药物，造福患者。”

成都先导董事长兼首席执行官李进博士表示：

“我们很高兴能与Bridge Biotherapeutics携手合作，利用成都先导世界领先的DEL平台，筛选出具有潜力的新颖药物候选物。期待双方团队紧密协作，各展所长，为加速推进新型抗癌药物研发贡献力量。”

目前，Bridge已经启动了针对非小细胞肺癌（NSCLC）的主要候选药物BBT-207的临床I期第四组试验。通过与成都先导开展合作，Bridge将着手开发新型抗癌药物，以加强其癌症治疗药物管线。

关于Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Inc.成立于2015年，在韩国和美国设有公司，是一家上市的临床阶段生物技术公司。Bridge致力于发现和开发新型疗法，专注于治疗需求高度未满足的疾病领域，包括纤维化疾病和癌症。公司正在开发用于治疗包括特发性肺纤维化（IPF）在内的纤维化疾病的新型自分泌运动因子抑制剂BBT-877，以及适用于EGFR C797S突变的非小细胞肺癌（NSCLC）的强效靶向治疗药物BBT-207。

了解更多信息，请访问：https://www.bridgebiorx.com/en/

关于成都先导

成都先导药物开发股份有限公司（上海证券交易所股票代码：688222.SH，股票名称：成都先导）致力于打造全球一流的创新型生物医药企业，总部位于中国成都，在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化，着力打造了国际领先的DNA编码化合物库技术（包括DEL库的设计、合成和筛选及拓展应用）平台，并拓展了基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、寡聚核酸新药研发相关技术（STO）和靶向蛋白降解相关技术（TPD）的核心技术平台。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式，成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前，公司有多个内部新药项目处于临床及临床前不同阶段。

了解更多信息，请访问：www.hitgen.com

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

· Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company “HitGen” to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program

· Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen’s proprietary DEL that are expected to exhibit potent anticancer activity

CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.

Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets. Over the past year, the company has established its own analytical methods through preliminary research to discover new targeted anticancer drugs that are expected to show high anticancer effects across various cancer types. With the launch of this joint research with HitGen, it is anticipated that the derivation of effective substances, optimization, and securing of lead compounds will progress rapidly within the next year.

HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology, and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world. The company has made tremendous improvements over the last few years, making it an integrated drug discovery company focusing on DEL, synthetic therapeutic oligonucleotide (STO), targeted protein degradation (TPD), fragment-based drug discovery and structure-based drug design (FBDD/SBDD).

James Lee, CEO of Bridge Biotherapeutics stated, "By collaborating with HitGen, we will accelerate the discovery of new targeted anticancer drugs." He added, "We will challenge ourselves to develop drugs that can provide anticancer treatment effects even for genetically mutated cancers, which have been difficult to develop until now."

Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc., expressed, " We are pleased to collaborate with Bridge Biotherapeutics team in generating novel drug candidates based on the screening platform we possess," and stated, "We will contribute to the acceleration of new anticancer drug discovery based on the expertise of both companies."

Bridge Biotherapeutics has initiated the fourth cohort in the Phase 1 clinical trial for its leading candidate drug BBT-207 for the treatment of non-small cell lung cancer. Through this collaboration with HitGen, the company is embarking on the discovery of new anticancer drugs as part of its efforts to strengthen its cancer portfolio.

About Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations.

Learn more at https://www.bridgebiorx.com/en/

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

For more information about HitGen, please visit www.hitgen.com.